ISSN 2054-4057
Now Accepting Submissions
..................................................................................
OA Drug Design & Delivery is a multidisciplinary open access 'peer reviewed' journal that publishes basic and clinical research concerning all aspects of drug design and delivery including:
In-Silico Drug Design
Combinatorial Chemistry
High-Throughput Screening
Drug Delivery
Drug Targets
Drug Structure-Activity Relationships
OA Drug Design & Delivery is committed to publishing high quality 'peer reviewed' manuscripts that illustrate the most important and 'cutting edge' developments in all areas of drug design and delivery.
The Journal welcomes original research articles, reviews, short communications, Editorial, Hypothesis, Methodology, Study protocols, Letter to editor, Meeting reports, Case report and case studies relevant to the various fields of Pharmaceutical Sciences and medicine.
We will facilitate article submission, rapid article quality assurance through 'peer review', article formatting and processing to a final product which will allow high visibility, impact and provoke debate.
This journal has adopted the following models:
- Creative Commons Attribution License (CC-BY 2.0 UK)
- Publication Integrity and Ethics (P.I.E.) Guidelines
- Ethical Rules of Disclosure of the Association for Medical Ethics (AME)
- ICMJE Recommendations of the International Committee of Medical Journal Editors (ICMJE)
- Editorial Policy Statements of the Council of Science Editors (CSE)
Tracked/indexed by:
Google Scholar, JournalTOCs, EZB Nutzeranfragen, RoMEO, CrossRef, CNKI, J-Gate
OAPL (UK) archiving provider: British Library
Our publisher has negotiated a discount for its editors, reviewers and authors to undertake (distant learning- fully online) short courses related to research integrity and publication ethics, law and medical ethics, research governance, good ethical practice, leadership and management. These courses are approved by the Publication Integrity & Ethics.
The Association for Medical Ethics promotes the care of patients absent of any consideration of financial gain or loss based on choice of surgical equipment, implant, manufacturer, hospital or surgery center.
OAPL has adopted the Ethical Rules of Disclosure of the Association for Medical Ethics for all its journals.
A UK-based not-for-profit organization promoting integrity and ethics in the publishing sector through its guidelines and code of conduct.
P.I.E.'s main aim is to pave the way for a better publishing ethical environment that sets out the standards of a good and ethical editorial behaviour.
Whilst P.I.E. (π) promotes editorial freedom, at the same time, it also ensures that this freedom is not violated by editorial misconduct and plagiarism.
OAPL authors may choose to include the
OAPL standard ethics statements
in their submitted articles. It is assumed that all submitted original research studies, research studies, hypothesis, methodologies, short communications, case studies, case reports & case series have been conducted to the highest ethical standards.
Mishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
High ImpactCaban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High ImpactIzat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High ImpactWadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High ImpactEsposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High ImpactSiddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High ImpactWadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High ImpactSiddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High ImpactCaban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High ImpactIzat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High ImpactEsposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High ImpactMishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
High ImpactMishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
High ImpactCaban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High ImpactIzat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High ImpactWadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High ImpactEsposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High ImpactSiddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High ImpactRead about the
OAPL (UK) Code of Conduct for Editors
OAPL (UK) Press Centre- Publishing Director
OAPL (UK) and its journals support the following reporting guidelines for specific study designs:
CONSORT: Consolidated Standards of Reporting Trials
STARD: STAndards for the Reporting of Diagnostic accuracy studies
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
STROBE: STrengthening the Reporting of OBservational studies in Epidemiology
MOOSE: Meta-analysis of Observational Studies in Epidemiology
MIBBI: Minimum Information for Biological and Biomedical Investigations
ICTRP: International Clinical Trials Registry Platform
PROSPERO: International prospective register of systematic reviews
Copyright © 2013 - 2020 OAPL (UK)